clinical trial · NCT05581030
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
H. Lee Moffitt Cancer Center and Research Institute·phase1·recruiting·n = 7
Acute Lymphoblastic LeukemiaHyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)Calaspargase PegolRituximab
brief summary
The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.
started
May 1, 2023
primary completion
Oct 1, 2026
completion
Oct 1, 2026
last updated
Mar 6, 2026
official title
A Single-Arm, Open-Label Phase 1b Study of Hyper-CVAD + Calaspargase Pegol in Young Adults With Newly Diagnosed Acute Lymphoblastic Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol